Major pharmas post mixed third-quarter results

Share this article:

Many of the world's largest pharmaceutical companies reported mixed third-quarter results this week.
Net incomes rose at Amgen, Johnson & Johnson, Novartis and Eli Lilly but slipped at Pfizer and Abbott. Revenue and sales results at the companies varied.
Pfizer said Thursday its third-quarter net income fell to $1.5 billion from $3.3 billion. The company's largest division, Human Health, saw worldwide revenues decline 7 percent in the third quarter, compared to the same period last year.
Abbott's third-quarter net income fell 15 percent, but revenues were up 15 percent on sales of its arthritis drug Humira (adalimumab) at $356 million and a more than doubling of sales of arthritis drug Mobic (meloxicam) to $310 million.
Amgen reported its third-quarter net income more than tripled to $967 million from $236 million in the same period a year earlier. Much of the growth reflected soaring sales of its cancer drug Aranesp (darbepoetin alfa), which pulled in sales of $840 million in the quarter, up 38 percent from $608 million a year earlier.
Johnson & Johnson reported a 12 percent increase in third- quarter net income, but sales of the company's prescription drugs declined 0.5 percent to $5.5 billion due to increased competition from generics.
At Novartis, third-quarter net income totaled $1.7 billion, up from $1.5 billion a year earlier. Global sales of prescription drugs rose 10 percent to $5.1 billion while generic revenues, boosted by the recent acquisition of its Sandoz unit, more than doubled to $1.5 billion.
Lilly's third-quarter net income grew to $795 million from $755 millio, the year prior. Sales of its anti-psychotic Zyprexa (olanzapine) rose 1 percent to $1 billion while sales of attention deficit hyperactivity disorder drug Strattera (atomoxetine HCl) fell 14 percent from a year ago to $140 million.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions